Compare SRTA & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRTA | FLGT |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | 601 | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 530.4M | 579.9M |
| IPO Year | N/A | 2016 |
| Metric | SRTA | FLGT |
|---|---|---|
| Price | $5.79 | $19.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $7.81 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 1.1M | 304.0K |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | $39.27 | $10.09 |
| Revenue Next Year | $8.52 | $12.18 |
| P/E Ratio | $9.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.85 | $13.46 |
| 52 Week High | $6.50 | $31.04 |
| Indicator | SRTA | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 45.15 |
| Support Level | $4.91 | $17.64 |
| Resistance Level | $5.89 | $20.10 |
| Average True Range (ATR) | 0.27 | 0.78 |
| MACD | 0.09 | -0.22 |
| Stochastic Oscillator | 65.63 | 59.24 |
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.